The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 25, 2020
Filed:
Jun. 29, 2016
Applicant:
Genmab A/s, Copenhagen V, DK;
Inventors:
Jan Van De Winkel, Zeist, NL;
Tom Vink, Alphen aan den Rijn, NL;
Janine Schuurman, Diemen, NL;
Paul Parren, Odijk, NL;
Rob Aalberse, Duivendrecht, NL;
Marijn Van Der Neut Kolfschoten, Amsterdam, NL;
Assignee:
Genmab A/S, Copenhagen V, DK;
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C12P 21/08 (2006.01); C07K 16/28 (2006.01); A61K 51/10 (2006.01); A61K 47/68 (2017.01); C07K 16/16 (2006.01); C07K 16/18 (2006.01); C07K 1/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2887 (2013.01); A61K 47/6803 (2017.08); A61K 47/6813 (2017.08); A61K 47/6835 (2017.08); A61K 47/6839 (2017.08); A61K 47/6845 (2017.08); A61K 47/6849 (2017.08); A61K 51/10 (2013.01); A61K 51/103 (2013.01); A61K 51/1006 (2013.01); A61K 51/1021 (2013.01); A61K 51/1027 (2013.01); A61K 51/1039 (2013.01); C07K 16/00 (2013.01); C07K 16/16 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/94 (2013.01);
Abstract
The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).